Year-end Sale % OFF 
Abstract
Purpose: The 2018 NICE guidelines [1] advocate 3 monthly cardiac monitoring during adjuvant trastuzumab and 6 monthly for 2 years following completion of therapy. Cardiac monitoring in the metastatic setting is at the clinician’s discretion. Our aims: (1)To audit local and national trastuzumab cardiac monitoring in the adjuvant setting compared with the 2018 NICE guidelines. (2)To review variation in practice nationally when monitoring metastatic patients.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
